Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001641172-25-025979
Filing Date
2025-08-29
Accepted
2025-08-29 16:05:23
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 8132
2 EX-99.1 ex99-1.htm EX-99.1 12523
  Complete submission text file 0001641172-25-025979.txt   22519
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Subject) CIK: 0001374690 (see all company filings)

EIN.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-88225 | Film No.: 251280812
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address ONE BOSTON PLACE SUITE 2600 BOSTON MA 02108
Business Address ONE BOSTON PLACE SUITE 2600 BOSTON MA 02108 617-904-9195
Opaleye Management Inc. (Filed by) CIK: 0001595855 (see all company filings)

EIN.: 205648796 | State of Incorp.: MA | Fiscal Year End: 1231
Type: SCHEDULE 13G